San Francisco, CANCT06654882Now EnrollingIRB Ready

Polyarticular Course Juvenile Idiopathic Arthritis (JIA) Clinical Trial in San Francisco, CA

Access cutting-edge polyarticular course juvenile idiopathic arthritis (jia) treatment through this clinical trial at a research site in San Francisco. Study-provided care at no cost to qualified participants.

Sponsored by Duke University

Quick Self-Assessment

See if you qualify for this San Francisco location

Preparing your pre-screening questions…

Expert Care in San Francisco

Access polyarticular course juvenile idiopathic arthritis (jia) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related polyarticular course juvenile idiopathic arthritis (jia) treatment provided free

Apply for This San Francisco Location

Check if you qualify for this polyarticular course juvenile idiopathic arthritis (jia) clinical trial in San Francisco, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to San Francisco

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit San Francisco site if eligible
  4. 4Begin participation

About This Polyarticular Course Juvenile Idiopathic Arthritis (JIA) Study in San Francisco

This study is an open-label, randomized, multicenter trial that incorporates a multi-arm design comparing each of 3 non-TNFi (Tumor Necrosis Factor inhibitor) medications to a second TNFi (active control) within a sequential multiple assignment randomized trial design with 2 randomization stages corresponding with clinical decision points. The first randomization addresses whether each of the 3 non-TNFi medications is superior to treatment with a second TNFi. The second randomization allows identification of optimal sequential use of biologics (treatment strategies).

Sponsor: Duke University

Who Can Participate

Inclusion Criteria

Polyarticular course JIA
Moderate or high-disease activity (cJADAS10 \>5) despite treatment with an initial TNFi for ≥3 months
Age ≥2 years and \<18 years and weight ≥ 10kg
No systemic glucocorticoids or systemic glucocorticoids at a stable dose of ≤0.2 mg/kg/day (maximum 10 mg/day) for ≥2 weeks prior to baseline visit
Documented informed consent/assent obtained from the parent/caregiver/patient

Exclusion Criteria

Systemic JIA
Enthesitis-related arthritis/juvenile spondyloarthritis (2001 International League of Associations for Rheumatology \[ILAR\] criteria)30
History of or currently active inflammatory bowel disease
History of or currently active psoriasis
Active uveitis within 3 months of the baseline visit
History of or currently active sacroiliitis
History of or current malignancy
Active tuberculosis (TB) or a history of incompletely treated TB; Purified Protein derivative (PPD) or QuantiFERON-TB positive patients (without active TB) unless it is documented that the patient has been adequately treated for TB and can start treatment with a biologic agent, based on the medical judgment of the site investigator and/or an infectious disease specialist; suspected extrapulmonary TB infection; or at high risk of contracting TB, such as close contact with individual with active or latent TB
Prior treatment with more than one TNFi molecule; exposure to more than one biosimilar of the same TNFi molecule is allowed
Prior treatment with non-TNFi bDMARDs and/or any JAKi
Aspartate aminotransferase (AST) or alanine transaminase (ALT) ≥3 × upper limit of normal (ULN) for age and sex
Serum creatinine \>1.5 × ULN for age and sex
Platelet count \<150 × 103/μL (\<150,000/mm3)
Hemoglobin \<7.0 g/dL (\<4.3 mmol/L)
White blood cell (WBC) count \<3,000/mm3 (\<3.0 × 109/L)
Neutrophil count \<1,500/mm3 (\<1.5 × 109/L)
Any active acute, subacute, chronic, or recurrent bacterial, viral, or systemic fungal infection or any major episode of infection requiring hospitalization or treatment during screening or treatment with IV antibiotics completed within 4 weeks of the screening visit or oral antibiotics completed within 2 weeks of the screening visit
Any medical history that may be considered a contraindication/safety concern with the use of adalimumab, etanercept, tofacitinib, ABA, or an IL-6 inhibitor or their biosimilars, in the opinion of the site investigator

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in San Francisco?

Yes, this clinical trial (NCT06654882) has an active research site in San Francisco, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Polyarticular Course Juvenile Idiopathic Arthritis (JIA) Treatment Options in San Francisco, CA

If you're searching for polyarticular course juvenile idiopathic arthritis (jia) treatment options in San Francisco, CA, this clinical trial (NCT06654882) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our San Francisco research site is actively enrolling participants for this clinical trial. You'll receive care from experienced polyarticular course juvenile idiopathic arthritis (jia) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all polyarticular course juvenile idiopathic arthritis (jia) clinical trials near you to find additional studies recruiting in your area.

More Interstitial Cystitis Trials in San Francisco, CA

See all interstitial cystitis clinical trials recruiting in San Francisco — not just this study.

Browse Interstitial Cystitis Trials in San Francisco →

Browse More Trials by Condition

Interstitial Cystitis TrialsJuvenile Arthritis TrialsAll Conditions →

Ready to Join in San Francisco?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · San Francisco, CA